Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Uncategorized

Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast

BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 28, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022 .